FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211584303> ?p ?o ?g. }

• W3211584303 endingPage "3425" @default.
• W3211584303 startingPage "3425" @default.
• W3211584303 abstract "Abstract Background: The FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid leukemia (AML) patients either by internal tandem duplication (ITD) or by point mutations in the tyrosine kinase domain (TKD). PHI-101 is a Type I FLT3 inhibitor developed to overcome resistance in AML. PHI-101 showed potent cellular activity in vitro and in vivo for both FLT3 ITD mutations and a wide variety of FLT3 point mutations in TKD. In preclinical studies utilizing primary human FLT3-ITD leukemia cells, PHI-101 showed increased anti-leukemic activity compared to gilteritinib based on increased survival in mice transplanted with these samples. The Phase 1a and Phase 1b global clinical trial with PHI-101 (NCT04842370) is currently underway to assess the overall safety and efficacy of PHI-101 in refractory and relapsed AML. Study Design and Methods: The overall design of the AML clinical trial consists of two parts, phase 1a, the dose-escalation, and phase 1b, the dose-expansion trial utilizing oral PHI-101 tablets. Up to 5 dose levels are planned for phase 1a and a single subject enrolled per dose level until the occurrence of at least one subject with more than Grade 2 toxicity according to CTCAE5.0 criteria during the 28-day evaluation period. The dose escalation will then convert to a standard 3+3 scheme, with 3 to 6 subjects per dose level cohort over the 28-day cycle. If there are no dose-limiting toxicities (DLT), dose escalation to the next higher dose levels will proceed upon the recommendation of the Safety Monitoring Committee. Subjects with FLT3 mutations or FLT3 wild-type will be enrolled in the dose-escalation cohort, and blood samples are collected for the primary endpoint pharmacokinetics (PK) and for the exploratory pharmacodynamic (PD) endpoint evaluation, including plasma inhibitory assay and biomarker analysis. Results: The Phase 1a clinical trial of PHI-101 was initiated in June 2020 at a daily dose of 40mg for level 1. As of July 31, 2021, 8 patients with relapsed or refractory AML have been enrolled in the trial, all of whom had prior anti-leukemic treatments with intensive chemotherapy, hypomethylating agents and/or other FLT3 inhibitors. To date, 5 enrolled patients were available for safety assessment at three dose levels and have not experienced any dose-limiting toxicities (DLTs) from repeating doses of the 28-day DLT-assessment window. The leukemic blasts in marrow or peripheral blood were dramatically reduced by up to 98% with one cycle (28 days). The pharmacokinetic data of plasma PHI-101 varied in a dose-proportional manner and peak plasma concentrations (Cmax) were reached between 4 and 6 hours after once-daily dosing. The pharmacodynamic evaluation by plasma inhibitory assay showed that plasma from patients receiving at daily doses of PHI-101 inhibited more than 90% of the phosphorylation of the FLT3-ITD receptor. PHI-101 was well tolerated with these dose levels. This study is currently recruiting FLT3 mutation or wild-type AML patients at multiple sites in Korea and Australia. Conclusion: PHI-101 is a next-generation FLT3 inhibitor that showed a potent anti-leukemic activity and improved efficacy in primary AML samples harboring FLT3/ITD and FLT3/TKD mutations in preclinical studies. The current analysis of this trial indicated that PHI-101 is a very effective FLT3 inhibitor for both refractory and relapsed AML patients, including those that have relapsed on other FLT3 TKI. The assessments of safety, tolerability, and PK of PHI-101 to determine the recommended dose for expansion are ongoing in the Phase 1a clinical trial. Disclosures Lee: Astellas Pharma, Inc.: Consultancy, Honoraria, Other: Advisory board; AbbVie: Honoraria, Other: Advisory board; Korean Society of Hematology: Membership on an entity's Board of Directors or advisory committees. Im: Pharos iBio Co., Ltd.: Current Employment. Nam: Pharos iBio Co., Ltd.: Current holder of individual stocks in a privately-held company. Kim: Pharos iBio Co., Ltd.: Current holder of individual stocks in a privately-held company. Han: Pharos iBio Co., Ltd.: Current holder of individual stocks in a privately-held company. Yoon: Pharos iBio Co., Ltd.: Current holder of individual stocks in a privately-held company. Small: Pharos iBio Co., Ltd.: Consultancy, Other: Scientific Advisory Board. The arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies, Research Funding; InSilico Medicine: Other: Scientific Advisory Board." @default.
• W3211584303 created "2021-11-22" @default.
• W3211584303 creator A5000278865 @default.
• W3211584303 creator A5001916257 @default.
• W3211584303 creator A5006965339 @default.
• W3211584303 creator A5012675709 @default.
• W3211584303 creator A5015765579 @default.
• W3211584303 creator A5016807045 @default.
• W3211584303 creator A5018989541 @default.
• W3211584303 creator A5027475930 @default.
• W3211584303 creator A5031233050 @default.
• W3211584303 creator A5041004365 @default.
• W3211584303 creator A5042974964 @default.
• W3211584303 creator A5045365096 @default.
• W3211584303 creator A5045941652 @default.
• W3211584303 creator A5061141053 @default.
• W3211584303 creator A5064780831 @default.
• W3211584303 creator A5067299268 @default.
• W3211584303 creator A5071144505 @default.
• W3211584303 creator A5091065629 @default.
• W3211584303 date "2021-11-05" @default.
• W3211584303 modified "2023-09-30" @default.
• W3211584303 title "A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia" @default.
• W3211584303 doi "https://doi.org/10.1182/blood-2021-149395" @default.
• W3211584303 hasPublicationYear "2021" @default.
• W3211584303 type Work @default.
• W3211584303 sameAs 3211584303 @default.
• W3211584303 citedByCount "0" @default.
• W3211584303 crossrefType "journal-article" @default.
• W3211584303 hasAuthorship W3211584303A5000278865 @default.
• W3211584303 hasAuthorship W3211584303A5001916257 @default.
• W3211584303 hasAuthorship W3211584303A5006965339 @default.
• W3211584303 hasAuthorship W3211584303A5012675709 @default.
• W3211584303 hasAuthorship W3211584303A5015765579 @default.
• W3211584303 hasAuthorship W3211584303A5016807045 @default.
• W3211584303 hasAuthorship W3211584303A5018989541 @default.
• W3211584303 hasAuthorship W3211584303A5027475930 @default.
• W3211584303 hasAuthorship W3211584303A5031233050 @default.
• W3211584303 hasAuthorship W3211584303A5041004365 @default.
• W3211584303 hasAuthorship W3211584303A5042974964 @default.
• W3211584303 hasAuthorship W3211584303A5045365096 @default.
• W3211584303 hasAuthorship W3211584303A5045941652 @default.
• W3211584303 hasAuthorship W3211584303A5061141053 @default.
• W3211584303 hasAuthorship W3211584303A5064780831 @default.
• W3211584303 hasAuthorship W3211584303A5067299268 @default.
• W3211584303 hasAuthorship W3211584303A5071144505 @default.
• W3211584303 hasAuthorship W3211584303A5091065629 @default.
• W3211584303 hasConcept C121608353 @default.
• W3211584303 hasConcept C126322002 @default.
• W3211584303 hasConcept C142424586 @default.
• W3211584303 hasConcept C143998085 @default.
• W3211584303 hasConcept C203092338 @default.
• W3211584303 hasConcept C2778461978 @default.
• W3211584303 hasConcept C2778729363 @default.
• W3211584303 hasConcept C2778820342 @default.
• W3211584303 hasConcept C29730261 @default.
• W3211584303 hasConcept C31760486 @default.
• W3211584303 hasConcept C535046627 @default.
• W3211584303 hasConcept C71924100 @default.
• W3211584303 hasConcept C86803240 @default.
• W3211584303 hasConcept C87355193 @default.
• W3211584303 hasConcept C98274493 @default.
• W3211584303 hasConceptScore W3211584303C121608353 @default.
• W3211584303 hasConceptScore W3211584303C126322002 @default.
• W3211584303 hasConceptScore W3211584303C142424586 @default.
• W3211584303 hasConceptScore W3211584303C143998085 @default.
• W3211584303 hasConceptScore W3211584303C203092338 @default.
• W3211584303 hasConceptScore W3211584303C2778461978 @default.
• W3211584303 hasConceptScore W3211584303C2778729363 @default.
• W3211584303 hasConceptScore W3211584303C2778820342 @default.
• W3211584303 hasConceptScore W3211584303C29730261 @default.
• W3211584303 hasConceptScore W3211584303C31760486 @default.
• W3211584303 hasConceptScore W3211584303C535046627 @default.
• W3211584303 hasConceptScore W3211584303C71924100 @default.
• W3211584303 hasConceptScore W3211584303C86803240 @default.
• W3211584303 hasConceptScore W3211584303C87355193 @default.
• W3211584303 hasConceptScore W3211584303C98274493 @default.
• W3211584303 hasIssue "Supplement 1" @default.
• W3211584303 hasLocation W32115843031 @default.
• W3211584303 hasOpenAccess W3211584303 @default.
• W3211584303 hasPrimaryLocation W32115843031 @default.
• W3211584303 hasRelatedWork W1608269846 @default.
• W3211584303 hasRelatedWork W2406230970 @default.
• W3211584303 hasRelatedWork W2557725129 @default.
• W3211584303 hasRelatedWork W2775730895 @default.
• W3211584303 hasRelatedWork W2974945014 @default.
• W3211584303 hasRelatedWork W2998104471 @default.
• W3211584303 hasRelatedWork W3092926650 @default.
• W3211584303 hasRelatedWork W4254153790 @default.
• W3211584303 hasRelatedWork W4311669467 @default.
• W3211584303 hasRelatedWork W90644059 @default.
• W3211584303 hasVolume "138" @default.
• W3211584303 isParatext "false" @default.
• W3211584303 isRetracted "false" @default.
• W3211584303 magId "3211584303" @default.
• W3211584303 workType "article" @default.